Acumen Pharmaceuticals, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Acumen Pharmaceuticals adopted an Amended and Restated 2021 Equity Incentive Plan on June 3, 2026. The plan increases the share reserve to 10,000,000 shares plus an Available Reserve of up to 1,433,852 shares plus Returning Shares (capped at 19,040,630 shares minus Available Reserve), permitting grants of incentive stock options, nonstatutory options, SARs, RSUs, restricted stock, and performance awards to employees, directors, and consultants. The document provides detailed grant notice templates and terms but does not specify dollar amounts, new grants made, or share counts actually issued under the plan.
Why this rating
Plan amendment is routine equity administration. No concrete grants, valuations, or share issuance disclosed. Share reserve increase relative to $45.3M market cap is moderate but typical for small-cap biotech. Standard boilerplate plan documentation.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.